Psychedelic compounds are gaining traction as potential clinical tools for addressing medical health complaints. Danny Gelman provides his insights on the regulatory landscape and the potential for patent protection in this rapidly evolving sector for Healthcare Markets International.
This interview was originally posted by Nick Herbert, Editor of HealthcareMarkets International (HMi) at LaingBuisson on 8 May 2022.
The wider use of psychedelic compounds in healthcare has many regulatory hurdles to overcome before it can realise its potential as a clinical tool for addressing medical health complaints. HMi caught up with Danny Gelman, Senior Associate with FPA. Click here to read the interview.